SCHEMBL4470329

SCHEMBL4470329

COc1cc(=O)n(-c2c(F)cccc2F)c(C)c1CCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.41
GNRHR P30968 6/20 0.39
PLA2G4A P47712 1/20 0.38
P2RX7 Q99572 2/20 0.37
NR1H2 P55055 2/20 0.37
NR1H3 Q13133 2/20 0.37
TAAR1 Q96RJ0 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4469946 0.79 MAPK14 (0.41) PARK7GNRHRNPC1RAB9ASMN1; SMN2
SCHEMBL14530708 0.67 TTR (0.43) KDM4EALDH1A1SMN1; SMN2
SCHEMBL27302478 0.66 ABCB1 (0.54) TAAR1KMT2A
SCHEMBL14533759 0.64 SMN1; SMN2 (0.51) SMN1; SMN2
SCHEMBL22050353 0.64 KDM4E (0.52) TAAR1KDM4EALDH1A1TDP1NPC1
SCHEMBL3606088 0.61 POLB (0.48) KMT2A
SCHEMBL353840 0.61 BCL2 (0.48) KDM4E
SCHEMBL8464452 0.60 HTR1A (0.55) TAAR1
SCHEMBL2030206 0.60 MAPK13 (0.46) KDM4EMEN1ALDH1A1KMT2ATDP1
Methylamine SCHEMBL10385050 0.59 CYP19A1 (0.71) NR1H2NR1H3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490064-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE Pharmacia Corporation (US) 2004-12-29 EP claimed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US claimed
WO-2003068230-A1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORPORATION (US) 2003-08-21 WO claimed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 PARK7 133/4885GNRHR 3965/4885PLA2G4A 1543/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 PARK7 225/4885GNRHR 3722/4885PLA2G4A 1218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.